Kanjinti (trastuzumab) Injection, 150 mg/vial, Powder for Single-Dose Vial
Kanjinti is a sterile, preservative-free powder for injection containing 150 mg of trastuzumab per single-dose vial. It is a biosimilar to Herceptin, used for the treatment of HER2-overexpressing breast cancer and metastatic gastric cancer. The product is supplied as a lyophilized powder that must be reconstituted and diluted prior to intravenous administration.
Vendor Pricing Comparison
Sorted by lowest price · Add now, sign in at checkout
Vendor Pricing Comparison
Sorted by lowest price · Add now, sign in at checkout
Kanjinti is a sterile, preservative-free powder for injection containing 150 mg of trastuzumab per single-dose vial. It is a biosimilar to Herceptin, used for the treatment of HER2-overexpressing breast cancer and metastatic gastric cancer. The product is supplied as a lyophilized powder that must be reconstituted and diluted prior to intravenous administration.
1 vendor
